122 related articles for article (PubMed ID: 37677942)
21. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Holdsworth MT; Raisch DW; Winter SS; Chavez CM
Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
[TBL] [Abstract][Full Text] [Related]
24. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice.
Badarudin NS; Mohamed Shah N; Mohd Kassim KNB; Ismail F; Islahudin F; Mohd Tahir NA; Yusak S
Support Care Cancer; 2022 Jun; 30(6):5339-5349. PubMed ID: 35290510
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.
Patel P; Lavoratore SR; Flank J; Kemp M; Vennettilli A; Vol H; Taylor T; Zelunka E; Maloney AM; Nathan PC; Dupuis LL
Support Care Cancer; 2020 Feb; 28(2):933-938. PubMed ID: 31177392
[TBL] [Abstract][Full Text] [Related]
29. Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology. Interim results of a multicenter crossover study.
Reindl TK; Geilen W; Hartmann R; Wiebelitz KR; Kan G; Wilhelm I; Lugauer S; Behrens C; Weiberlenn T; Hasan C; Gottschling S; Wild-Bergner T; Henze G; Driever PH
Support Care Cancer; 2006 Feb; 14(2):172-6. PubMed ID: 16021478
[TBL] [Abstract][Full Text] [Related]
30. Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies.
Celio L; Bonizzoni E; De Braud F; Agustoni F; Aapro M
Support Care Cancer; 2016 Mar; 24(3):1025-34. PubMed ID: 26245497
[TBL] [Abstract][Full Text] [Related]
31. Computerized system for outcomes-based antiemetic therapy in children.
Holdsworth MT; Adams VR; Raisch DW; Wood JG; Winter SS
Ann Pharmacother; 2000 Oct; 34(10):1101-8. PubMed ID: 11054974
[TBL] [Abstract][Full Text] [Related]
32. [Anti-leukemia activity of T cells impacted by dendritic cells added with sodium selenite].
Yang L; Liu FQ; Wang JW; Wu YP; Ding J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):892-7. PubMed ID: 18718085
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
34. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
35. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.
Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C
Support Care Cancer; 2003 Aug; 11(8):516-21. PubMed ID: 12836088
[TBL] [Abstract][Full Text] [Related]
36. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
D'Souza A; Pawar D; Ramaswamy A; Turkar S; Bhargava P; Kapoor A; Mandavkar S; Nashikkar C; Ostwal V
South Asian J Cancer; 2020 Oct; 9(4):240-244. PubMed ID: 34131576
[No Abstract] [Full Text] [Related]
39. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron.
Santini D; Vincenzi B; Fossati C; D'Angelillo RM; Patti G; Bianco V; Avvisati G; Tonini G
Med Oncol; 2001; 18(2):131-5. PubMed ID: 11778758
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]